CAR-T（CAR-T）细胞疗法在非肿瘤性疾病中的应用
Chimeric antigen receptor T (CAR-T) cell therapy in non-oncological diseases.
CAR-T（CAR-T）细胞在血液系统恶性肿瘤中的应用推动了这种免疫治疗形式的显著进展。
CELL INTELLIGENCE · 肿瘤细胞治疗研究
肿瘤细胞治疗研究
价格与偏见？嵌合抗原受体（CAR）T 细胞疗法的价值
英文原题：Price and Prejudice? The Value of Chimeric Antigen Receptor (CAR) T-Cell Therapy.
查看英文原题
Price and Prejudice? The Value of Chimeric Antigen Receptor (CAR) T-Cell Therapy.
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
中文摘要
尽管嵌合抗原受体（CAR）T细胞疗法在淋巴瘤患者中具有较高缓解率，但其成本效果仍有争议，原因包括价格高昂且临床证据存在不确定性。除CAR-T 疗法本身购置成本较高外，考虑到细胞因子释放综合征等不良事件发生频率，操作和设施成本也会增加经济负担。临床研究随访期相较传统癌症药物较短。此外，缺乏直接头对头比较疗效数据；这对于评估新疗法成本效果非常重要。还需要更多证据弥补现有临床数据的不确定性，才能全面评估长期疗效、安全性和比较疗效。
展开英文摘要原文
Although chimeric antigen receptor (CAR) T-cell therapy has shown a high response rate in lymphoma patients, its cost-effectiveness is controversial due to the high price and uncertainty of the clinical evidence.
In addition to the high acquisition cost of CAR T-cell therapy, procedure and facility cost increase the financial burden considering the frequency of adverse events such as cytokine release syndrome. In clinical research, relatively short follow-up periods were used compared to traditional cancer agents.
In addition, head-to-head comparative effectiveness data are unavailable, which is an important factor when evaluating the cost-effectiveness of a new treatment. Additional evidence that will compensate for the uncertainty of existing clinical data is needed for full evaluation of long-term efficacy, safety, and comparative effectiveness.
论文信息
- 作者
- Choi G、Shin G、Bae S
- 单位
- College of Pharmacy, Ewha Womans University, Seoul 03760, Korea.South Korea
- 文献类型
- 非美国政府资助研究
- 期刊
- International journal of environmental research and public health2022 Sep 28
- 原文标识
- PubMed 36231661 · DOI 10.3390/ijerph191912366
在 PubMed 查看 → 出版商原文（DOI） 全文 PDF（PMC）· 可下载 治疗专题与资料阅读指南 资料来源与翻译说明 报告译文或资料问题 →